These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 24630573)

  • 1. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive value of anti-Mullerian hormone levels in serum and follicle fluid for IVF-ET outcomes in patients with polycystic ovarian syndrome].
    Chen X; Yin M; Ye D; He Y; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):546-9. PubMed ID: 23644117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
    Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism.
    Eldar-Geva T; Margalioth EJ; Gal M; Ben-Chetrit A; Algur N; Zylber-Haran E; Brooks B; Huerta M; Spitz IM
    Hum Reprod; 2005 Jul; 20(7):1814-9. PubMed ID: 15802320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
    Tal R; Seifer DB; Khanimov M; Malter HE; Grazi RV; Leader B
    Am J Obstet Gynecol; 2014 Jul; 211(1):59.e1-8. PubMed ID: 24593938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
    Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive model of IVF outcomes for polycystic ovarian morphology and polycystic ovary syndrome in GnRH antagonist protocol using AMH-MoM and ovarian sensitivity index.
    Ko YR; Yu EJ; Park JE; Park JK; Eum JH; Kim TH; Lee WS; Lee HJ
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1667-1674. PubMed ID: 38937259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Müllerian hormone dynamics during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Dąbkowska-Huć A; Lemm M; Sikora J; Witek A; Skałba P
    Endokrynol Pol; 2013; 64(3):203-7. PubMed ID: 23873424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes and correlations of anti-Müllerian hormone and stem-cell factors in different ovarian reserve patients during GnRH-antagonist protocol and the effects on controlled ovarian hyperstimulation outcomes.
    Liu XH; Wu XH; Yang S
    Arch Gynecol Obstet; 2019 Dec; 300(6):1773-1783. PubMed ID: 31631249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
    Tshzmachyan R; Hambartsoumian E
    J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.